ORIGINAL ARTICLE

Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer

Joshua D. Smith MD[1] [iD] | Megan L. Ludwig PhD[1] | Apurva D. Bhangale MS[1] |
Collin Brummel BS[1] | Paul L. Swiecicki MD[2,3] [iD] | Francis P. Worden MD[2,3] |
Steven B. Chinn MD, MPH[1,3] | Chaz L. Stucken MD[1] | Andrew J. Rosko MD[1,3] |
Mark E. P. Prince MD[1,3] [iD] | Kelly M. Malloy MD[1,3] | Keith A. Casper MD[1,3] |
Carol R. Bradford MD[1,3] | Douglas B. Chepeha MD[1,3] [iD] | Jennifer Shah MD[3,4] |
Caitlin A. Schonewolf MD[3,4] | Jonathon B. McHugh MD[3,5] |
Mukesh K. Nyati PhD[3,4] | Avraham Eisbruch MD[3,4] |
Michelle L. Mierzwa MD[3,4] | Matthew E. Spector MD[1,3] [iD] | J. Chad Brenner PhD[1,3] [iD]

[1]Department of Otolaryngology – Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA

[2]Division of Hematology & Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA

[3]Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA

[4]Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA

[5]Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA

Correspondence
J. Chad Brenner, Department of Otolaryngology – Head & Neck Surgery, University of Michigan, MSRB III, 1150 W. Medical Center Dr., Ann Arbor, MI 58109, USA.
Email: chadbren@med.umich.edu

Funding information
American Cancer Society; Foundation for the National Institutes of Health, Grant/Award Numbers: P30-CA046592, T32DC005356; Research and Education Foundation of the American Head and Neck Society

Abstract

Background: We sought to characterize early changes in CD8$^+$ tumor-infiltrating lymphocytes and tumor transcriptomes after induction cetuximab in a cohort with p16-positive oropharyngeal cancer on a phase II clinical de-escalation trial.

Methods: Tumor biopsies were obtained before and 1 week after a single cetuximab loading dose in eight patients enrolled in a phase II trial of cetuximab and radiotherapy. Changes in CD8$^+$ tumor-infiltrating lymphocytes and transcriptomes were assessed.

Results: One week after cetuximab, five patients (62.5%) had an increase in CD8$^+$ cell infiltration with a median (range) fold change of $+5.8$ (2.5–15.8). Three (37.5%) had unchanged CD8$^+$ cells (median [range] fold change of -0.85 [0.8–1.1]). In two patients with evaluable RNA, cetuximab induced rapid

This work has not been previously presented in a conference setting or submitted for peer review.

Matthew E. Spector and J. Chad Brenner contributed equally to this study.

------

tumor transcriptome changes in cellular type 1 interferon signaling and keratinization pathways.

Conclusions: Within 1 week, cetuximab induced measurable changes in pro-cytotoxic T-cell signaling and immune content.

KEYWORDS
CD8, cetuximab, HPV, oropharynx, TILs

1 | INTRODUCTION

The anti-EGFR antibody cetuximab remains a component of multi-agent treatment paradigms for primary, recurrent, and metastatic head and neck squamous cell carcinoma (HNSCC), albeit with overall modest response rates and survival benefit.[1-3] Cetuximab promotes anti-tumor immunologic activity through antibody-dependent cellular cytotoxicity (ADCC), priming NK cells and EGFR-specific cytotoxic T-lymphocytes to target malignant cells.[4] The immunologic activity of cetuximab has particular importance in a rapidly evolving era of immunotherapy for HNSCC.[5] Novel combinatorial trials of cetuximab with anti-PD-1 inhibitors have begun to emerge, suggesting potential synergy and improvement in patient outcomes in unresectable recurrent or metastatic (R/M) HNSCC.[6,7] As these new therapies are evaluated, there is a need to codevelop predictive biomarkers in order to facilitate patient selection onto the most effective therapy.

To date, most biomarker strategies in this space have leveraged pretreatment features and little attention has been paid to using midtreatment biomarker approaches. Without midtreatment biopsies, the temporal dynamics of how cetuximab treatment alters the tumor immune-microenvironment (TIME), and how these changes may influence activity of the PD-1/PD-L1 and CTLA-4 axes in HNSCC remain poorly understood. In two separate phase II trials of patients treated with cetuximab monotherapy, Jie et al. showed a dynamic increase in PD-1$^+$TIM-3$^+$ cytotoxic tumor-infiltrating lymphocytes (TILs) and FOXP3$^+$CTLA4$^+$ regulatory TILs in the HNSCC TIME 4 weeks after cetuximab infusion.[8,9] These TIL populations attenuated cetuximab-mediated ADCC in vitro and correlated with poor clinical response and outcomes. However, these TIME alterations were not uniform; other critical immune pathways altered by cetuximab likely exist and require further characterization. These pathways may mediate differential response to subsequent immunotherapies in patients with R/M HNSCC previously treated with cetuximab.[10,11]

A better understanding of TIME changes influenced by cetuximab could lead to the identification of immunotherapy combinations specifically tailored to the aberrations in a patient's unique TIME. Toward this goal, our objective in the present study was to evaluate change in CD8$^+$ TIL content and TIME transcriptomes after a single cycle induction dose of cetuximab nested in a phase II trial cohort of patients with p16-positive oropharynx cancer being treated with cetuximab and definitive radiotherapy.

2 | MATERIALS AND METHODS

This study was approved by the Michigan Medicine Institutional Review Board with a waiver of informed consent (HUM 00080561).

2.1 | Patient cohort and specimens

Included patients were prospectively enrolled in a multicenter phase II trial of cetuximab and definitive radiotherapy for low-risk p16-associated oropharynx cancer, of which the clinical characteristics, treatment plan, and results have previously been reported.[12] Tumor p16 positivity (≥70% tumor cells with strong and diffuse nuclear and cytoplasmic staining on immunohistochemistry [IHC]) was used as a surrogate marker for HPV status. Patients received a cetuximab induction loading dose (400 mg/m^2) 1 week prior to start of radiotherapy with concurrent weekly cetuximab (250 mg/m^2). Each patient had biopsies of the primary tumor obtained prior to the loading dose and approximately 1 week later. All serial biopsies were obtained prior to the start of definitive radiotherapy. Tumor tissue obtained from surgical biopsy of the primary tumor was formalin-fixed and paraffin-embedded (FFPE) and banked for the studies described below.[13]

The trial enrolled a total of 42 patients; our cohort included eight of these patients. Reasons for exclusion of remaining patients from our analysis included lack of matched pre- and post-cetuximab biopsy specimens, insufficient tumor tissue on pre- and post-cetuximab biopsy specimens, and exhaustion of available tumor

tissue from pre- and post-cetuximab biopsy specimens prior to CD8$^+$ TIL quantification and transcriptomic analysis.

2.2 | Immunohistochemistry for CD8$^+$ TILs

IHC for CD8$^+$ TILs was performed according to our lab's established heat-induced epitope retrieval protocol (CD8 antibody at 1:40 dilution [Novocastra VP-C320]).[13,14] Following hematoxylin and eosin (H&E) staining of sections from each FFPE block, our head and neck pathologist (Jonathon B. McHugh) identified partial TMA cores, those with extensive tumor necrosis, and those consisting of <50% parenchymal tumor, to exclude from CD8$^+$ TIL scoring and subsequent DNA/RNA isolation.[13,14] Intratumoral CD8$^+$ TIL subsets were manually counted by the first author (Joshua D. Smith) at 200× magnification (20× objective lens). Mean TIL counts per triplicate tumor cores were calculated and averaged as previously reported.[13,14] GraphPad Prism (San Diego, CA) software was used for summary descriptive statistics and to compare pre- and post-cetuximab induction dose TIL counts with Student's t test ($\alpha = 0.05$).

2.3 | Transcriptome sequencing and quantification

In total, we identified two tumor-normal tissue pairs with sufficient material from pre- and post-cetuximab induction dose biopsy specimens for molecular analysis. Regions of sections with >60% tumor content were identified from the corresponding H&E by pathologist Jonathon B. McHugh and regions were collected for RNA isolation using the Qiagen AllPrep Kit, as described.[15] RNA was subsequently advanced for next-generation sequencing (NGS) if samples met our previously defined quality standards by Qubit and Bioanalyzer analysis.[16,17] Total RNA was then submitted to the University of Michigan Advanced Genomics Core for library preparation and sequencing. Briefly, we used 500 ng of RNA for library preparations or as much RNA as was available with the Illumina TruSeq Stranded Total RNA library prep kit (Cat #: RS-122-2201/2). The protocol was followed exactly according to the manufacturer's recommendations, with a single modification that we used 14 PCR cycles to amplify the library prior to the final bead purification. The samples were then pooled and loaded on an Illumina HiSEQ4000 and paired end sequenced to 75 nucleotide length in each direction. A summary of sequencing quality statistics including total

unique mapped reads for each sample is provided in Table S1, Supporting Information. FPKM and TPM were quantified from the data as previously described.[18,19]

2.4 | CIBERSORT and gene set enrichment analysis

Immune cell infiltrate content from bulk RNAseq data was assessed using the CIBERSORT algorithm.[20] Gene set enrichment analysis (GSEA) was performed on all genes using the software GSEA v4.03 from the Broad Institute (http://software.broadinstitute.org/gsea/index.jsp). Pre-ranked gene lists were prepared based on the log$_2$-fold change in FPKM and the gene sets used were selected from the Molecular Signatures Database v7.0, including hallmark gene sets, motif gene sets, gene ontology (GO) gene sets, and oncogenic signatures gene sets.

3 | RESULTS

Our focused cohort consisted of eight patients, all of whom were male with minimal comorbidities, tobacco and alcohol use history (Table 1).[12] All patients completed protocol treatment without interruptions or delays. With a median (range) follow-up duration of 7.2 (4.9–11.1) years, all remain alive with no evidence of disease recurrence.

The mean (SD) CD8$^+$ TIL count among all patients was 101.3 (66.6) before and 270.1 (236) after cetuximab induction dose ($p = 0.07$) (Figure 1). Five of eight patients (62.5%) showed an increase in CD8$^+$ TILs after cetuximab loading dose, with a median (range) fold change of +5.8 (2.5–15.8). The remaining three patients (37.5%) had largely unchanged CD8$^+$ TILs after cetuximab induction dose, with a median (range) fold change of −0.85 (0.8–1.1) (Figure 1).

Transcriptome sequencing and GSEA was performed on pre- and post-cetuximab loading dose biopsy specimens for patients 1 and 2, the only two patients with sufficient tumor material remaining for transcriptome analysis. The tumors of these two patients showed a +15.7 and +6.5-fold change in CD8$^+$ TIL count after cetuximab loading dose, respectively (Figure 1). Patient 1's tumor showed a significant upregulation of transcripts involved in the innate immune response to IFN-α signaling, including interferon-induced protein 44 (*IFI44*, log$_2$ fold change 3.14) and lymphocyte antigen 6 family member E (*LY6E*, log$_2$ fold change 3.07) (Figure 2). Conversely, patient 1's tumor showed a concomitant downregulation of transcripts involved in epithelial cell keratinization, including small proline rich protein 2E

TABLE 1 Patient characteristics ($n = 8$)

Patient No.	Sex	Age, years	Charlson comorbidity index (CCI)	Primary site	T stage	N stage	M stage	Overall stage
1	Male	76	2	Tongue base	1	2b	0	3
2	Male	71	2	Tonsil	3	2b	0	4
3	Male	57	2	Tongue base	2	1	0	3
4	Male	55	2	Tongue base	2	2b	0	4
5	Male	61	2	Tongue base	2	2b	0	4
6	Male	60	3	Tonsil	2	2b	0	4
7	Male	53	2	Tonsil	2	2a	0	4
8	Male	68	3	Tongue base	2	2c	0	4

Note: All had p16-positive squamous cell carcinoma of the oropharynx. Patient 4 was a former tobacco user of <10 pack-years, the remaining patients were never-smokers. Patients were staged according to the American Joint Committee on Cancer (AJCC) 7th edition staging manual.


FIGURE 1 CD8$^+$ TIL content before (pre) and after (post) cetuximab induction dose, per patient (A). Mean (SD) CD8$^+$ TIL content before (pre) and after (post) cetuximab induction dose (B). Fold change in CD8$^+$ TIL content after cetuximab treatment (C). Representative tumor cores showing marked change in CD8$^+$ TILs before (D) and after (E) cetuximab treatment [Color figure can be viewed at wileyonlinelibrary.com]

(*SPRR2E*, log$_2$ fold change −4.17) and (*LCE3D*, log$_2$ fold change −3.32). Patient 2's tumor also showed downregulation of epithelial cell keratinization transcripts, including transglutaminase 3 (*TGM3*, log$_2$ fold change −6.89) and cornifelin (*CNFN*, log$_2$ fold change −6.20) but also transcripts essential for aerobic metabolism via the mitochondrial electron transport chain, including peptidyl-propyl isomerase F (*PPIF*, log$_2$ fold change −2.04). Transcripts essential to generation of adaptive immune responses to antigenic stimuli were significantly upregulated in the tumor of patient 2, including immunoglobulin heavy constant gamma 1 (*IGHG1*, log$_2$ fold change 4.55) and Bruton tyrosine kinase (*BTK*, log$_2$ fold change 2.23) (Figure 2). For a complete list of mapped transcripts and changes with cetuximab induction dose, see Tables S2 and S3.

4 | DISCUSSION

Our objective in the present study was to characterize the early changes in the TIME of patients with p16-positive oropharyngeal cancer after a single cetuximab infusion. We showed that cetuximab influenced rapid changes in CD8$^+$ TIL content and transcriptomic profiles in primary tumors that were measurable 1 week after initial infusion. Critically, different magnitudes of changing CD8$^+$ TIL content were observed in different patients. In three

FIGURE 2 GSEA plots showing transcriptomic programs significantly upregulated (A) or downregulated (B) after cetuximab loading dose in patients one and two. ES, enrichment score; FDR, false discovery rate [Color figure can be viewed at wileyonlinelibrary.com]

patients cetuximab did not alter $CD8^+$ TIL content, while increases were observed in the other five patients. As such, our findings are novel in that they suggest that TIME alterations that can be used to subdivide populations can be identified in a clinically relevant timeframe that would enable timely patient selection for a personalized combinatorial immunotherapy paradigm. For example, the tumors that had enhanced $CD8^+$ TIL content may benefit most from combined immunotherapy, while those with static or decreased content may better respond to other forms of intervention.

Jie et al. have previously shown that cetuximab induced reliable and reproducible changes in TIL populations approximately 4 weeks after cetuximab infusion that correlated with treatment response in patients with HNSCC.[8,9] After a single neoadjuvant cetuximab dose, patients whose tumors failed to respond to treatment showed a significant increase in $CD4^+FOXP3^+$ regulatory TILs that co-expressed the immunoinhibitory CTLA-4

and TGF-β proteins.[9] Concomitantly, poorly responsive tumors were characterized by a significant increase in $CD8^+$ TILs expressing PD-1 and TIM-3.[8] These TIME alterations were measured approximately 1 month after initial cetuximab infusion. The authors posited that the immunoinhibitory environment promoted by cetuximab in certain patients may be targeted by combinatorial blockade of PD-1, CTLA-4, and/or TIM-3 to break acquired resistance. Our data extends their discovery by suggesting that TIME alterations occur even earlier after initial cetuximab infusion.

An early biomarker timepoint of response to cetuximab would be a valuable tool when developing combinatorial regimens in HNSCC. In a single arm phase II trial, the combination of cetuximab and pembrolizumab had an impressive response rate compared to either agent alone, suggesting synergy in R/M HNSCC.[6] While an encouraging result, the TIME characteristics that predict poor rates and durability of response to this combination

are unknown. CD8$^+$ TIL content does correlate with response to immune checkpoint inhibition in various HNSCC populations,[21] but few studies have been able to assess how early dynamic changes in TIL content correlate with outcome.

Due to our small cohort size, we were not able to perform analysis to correlate change in CD8$^+$ TILs with response to cetuximab, recurrence, and survival. Further, our study utilized limited primary tumor biopsy specimens and our results thus do not account for the vast intra- and intertumor heterogeneity in HNSCC TIME immune cell content, spatial distribution and transcriptomic programs.[22] Tumor HPV positivity was determined solely by p16 IHC. While confirmatory HPV DNA ISH is not routinely indicated per expert guidelines, there is a small subset of p16 IHC positive tumors that lack HPV DNA.[23,24] We did not have sufficient tumor specimen to profile early alterations in markers of T-cell exhaustion in the TIME. Our transcriptomic data suggests that cetuximab induces rapid changes in transcriptional programs for diverse cellular processes related to epithelial cell differentiation and keratinization, oxidative phosphorylation, and innate and adaptive immune responses. However, we lacked sufficient tumor material for downstream validation of these findings, which could be a focus of future research in this area. Nevertheless, these preliminary findings provide support for further in-depth characterization of rapid changes induced by cetuximab and their potential utility as early predictive biomarkers. Indeed, with the recent technological advances in spatial transcriptomic analysis of FFPE specimens, early-treatment biomarkers have great potential in the near future.[25] Further, while our field is still in the early phases of advancing mid-treatment liquid (plasma, saliva, urine, etc.) biomarkers for cancer monitoring,[26–28] our data suggests that as trials for liquid biopsy based biomarkers are advancing, mid-treatment tumor biopsies may also be a useful tool for characterizing the biologic response to systemic therapy and assist with thoughtful development of improved, more precise immunomodulatory therapies.

5 | CONCLUSIONS

Herein, we showed that cetuximab induces rapid alterations in the TIME of primary HNSCC just 1 week after a single induction dose. In a rapidly evolving era of combinatorial immunotherapies for primary, recurrent, and metastatic HNSCC, we hypothesize that this early dynamic response in CD8$^+$ TIL content coupled with more in-depth characterization of tumor transcriptomic changes may serve as a useful, early biomarker for adaptive treatment selection paradigms.

CONFLICT OF INTEREST STATEMENT
The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID
Joshua D. Smith https://orcid.org/0000-0002-2076-7589
Paul L. Swiecicki https://orcid.org/0000-0003-2286-3555
Mark E. P. Prince https://orcid.org/0000-0002-1120-9008
Douglas B. Chepeha https://orcid.org/0000-0001-9062-3719
Matthew E. Spector https://orcid.org/0000-0001-7646-6075
J. Chad Brenner https://orcid.org/0000-0003-3238-1111

REFERENCES
1. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N Engl J Med*. 2006;354:567-578.
2. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med*. 2008;359(11):1116-1127.
3. Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomized, open-label, phase 3 study. *Lancet*. 2019;393:12-18.
4. Lee SC, Srivastava RM, Lopez-Albaitero A, Ferrone S, Ferris RL. Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. *Immunol Res*. 2011;50:248-254.
5. Taberna M, Oliva M, Mesia R. Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma. *Front Oncol*. 2019;9:383.
6. Sacco AG, Chen R, Worden FP, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. *Lancet Oncol*. 2021;22:883-892.

7. Ferris RL, Moskovitz J, Kunning S, et al. Phase I trial of cetuximab, radiation therapy, and ipilimumab in locally advanced head and neck cancer. *Clin Cancer Res.* 2022;28(7):1335-1344.

8. Jie H, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL. Increased PD-1[+] and TIM-3[+] TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients. *Cancer Immunol Res.* 2017;5(5):408-416.

9. Jie H, Schuler PJ, Lee SC, et al. CTLA-4[+] regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. *Cancer Res.* 2015;75(11):2200-2210.

10. Park J, Durbeck J, Clark JR, Faden DL. Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes. *Oral Oncol.* 2020;111:105024.

11. Ferris RL, Licitra L, Fayette J, et al. Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use. *Clin Cancer Res.* 2019;25(17):5221-5230.

12. Swiecicki PL, Li P, Bellile E, et al. Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin. *Head Neck.* 2020;42:1728-1737.

13. Hoesli R, Birkeland AC, Rosko AJ, et al. Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma. *Oral Oncol.* 2018;77:83-89.

14. Mann JE, Smith JD, Birkeland AC, et al. Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma. *Cancer Immunol Immunother.* 2019;68(2):213-220.

15. Birkeland AC, Foltin SK, Michmerhuizen NL, et al. Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma. *Oral Oncol.* 2017;68:5-8.

16. Birkeland AC, Yanik M, Tillman BN, et al. Identification of targetable ERBB2 aberrations in head and neck squamous cell carcinoma. *JAMA Otolaryngol Head Neck Surg.* 2016;142(6):559-567.

17. Tillman BN, Yanik M, Birkeland AC, et al. Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing. *Head Neck.* 2016;38:E1646-E1652.

18. Heft Neal ME, Bhangale AD, Birkeland AC, et al. Prognostic significance of oxidation pathway mutations in recurrent laryngeal squamous cell carcinoma. *Cancers (Basel).* 2020;12(11):3081.

19. Heft Neal ME, Gensterblum-Miller E, Bhangale AD, et al. Integrative sequencing discovers an ATF1-motif enriched molecular signature that differentiates hyalinizing clear cell carcinoma from mucoepidermoid carcinoma. *Oral Oncol.* 2021;117:105270.

20. Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. *Methods Mol Biol.* 2018;1711:243-259.

21. Lechner A, Schlosser H, Rothschild SI, et al. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. *Oncotarget.* 2017;8:44418-44433.

22. Canning M, Guo G, Yu M, et al. Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy. *Front Cell Dev Biol.* 2019;7:52.

23. Fakhry C, Lacchetti C, Rooper LM, et al. Human papillomavirus testing in head and neck carcinomas: ASCO clinical practice guideline endorsement of the College of American Pathologists guideline. *J Clin Oncol.* 2018;36(31):3152-3161.

24. Nauta IH, Rietbergen MM, van Bokhoven AAJD, et al. Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in The Netherlands and the importance of additional HPV DNA testing. *Ann Oncol.* 2018;29:1273-1279.

25. Villacampa EG, Larsson L, Mirzazadeh R, et al. Genome-wide spatial expression profiling in formalin-fixed tissues. *Cell Genomics.* 2021;1(3):100065.

26. Haring CT, Dermody SM, Yalamanchi P, et al. The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma. *Oral Oncol.* 2022;126:105776.

27. Flach S, Howarth K, Hackinger S, et al. Liquid biopsy for minimal residual disease detection in head and neck squamous cell carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. *Br J Cancer.* 2022;126(8):1186-1195.

28. Weidhaas JB, Harris J, Schaue D, et al. The *KRAS*-variant and cetuximab response in head and neck squamous cell cancer. A secondary analysis of a randomized clinical trial. *JAMA Oncol.* 2017;3(4):483-491.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.